This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks (Q4W) as intravitreal (IVT) injection in Chinese participants with nAMD.
Initial diagnosis of nAMD within 9 months prior to the screening visit
Previous treatment with at least three anti-vascular endothelial growth factor (VEGF) IVT injections for nAMD per standard-of-care (SOC) within 6 months prior to the screening visit
Demonstrated response to prior anti-VEGF IVT treatment since diagnosis
Availability of historical VA data prior to the first anti-VEGF treatment for nAMD up to the screening visit
History of vitrectomy surgery, submacular surgery, or other surgical intervention, all for AMD
Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy
Previous treatment with corticosteroid IVT injection or corticosteroid implants
Previous intraocular device implantation (not including intraocular lens implants)